Roche signs deal with Dyno Therapeutics for gene therapy vectors
Roche has signed a collaborative agreement with Dyno Therapeutics for the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) disease and liver-directed therapies.
Under the terms of the agreement, Dyno will design novel AAV capsids with improved functional properties for gene therapies, while Roche and its subsidiary Spark Therapeutics will be responsible for preclinical, clinical and commercialisation activities for gene therapy product candidates using the novel capsids.
Roche will pay Dyno an undisclosed upfront payment, as well as additional payments during the research phase of the collaboration.
In addition, Dyno is eligible to receive clinical and sales milestone payments and royalties for any resulting products, with all of these payments potentially exceeding $1.8bn.
Read more: http://www.pharmatimes.com/news/roche_signs_deal_with_dyno_therapeutics_for_gene_therapy_vectors_1353327
Under the terms of the agreement, Dyno will design novel AAV capsids with improved functional properties for gene therapies, while Roche and its subsidiary Spark Therapeutics will be responsible for preclinical, clinical and commercialisation activities for gene therapy product candidates using the novel capsids.
Roche will pay Dyno an undisclosed upfront payment, as well as additional payments during the research phase of the collaboration.
In addition, Dyno is eligible to receive clinical and sales milestone payments and royalties for any resulting products, with all of these payments potentially exceeding $1.8bn.
Read more: http://www.pharmatimes.com/news/roche_signs_deal_with_dyno_therapeutics_for_gene_therapy_vectors_1353327
